Recall: Losartan Potassium 100mg Tablets Due to Impurity NMBA
Legacy Pharmaceutical Packaging recalls Losartan Potassium 100mg tablets distributed by Wal-Mart due to the presence of impurity NMBA.
Stop using this now
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Contact the company
What happened, in plain English
Legacy Pharmaceutical Packaging LLC is recalling Losartan Potassium Tablets, USP, 100 mg, in 30 tablet bottles. The recall is due to Current Good Manufacturing Practice (CGMP) deviations that resulted in the detection of an impurity called N-Methylnitrosobutyric acid (NMBA). These specific bottles were distributed by Wal-Mart. Read more at govinfonow.com/recall/39134-recall-losartan-potassium-100mg-tablets-due-to-impurity-nmba.
Source Summary by GovInfoNow · govinfonow.com/recall/39134-recall-losartan-potassium-100mg-tablets-due-to-impurity-nmba · Updated October 11, 2026 · FDA enforcement record: FDA #D-1050-2019
Cite this page
“Recall: Losartan Potassium 100mg Tablets Due to Impurity NMBA.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/39134-recall-losartan-potassium-100mg-tablets-due-to-impurity-nmba. Based on FDA recall #D-1050-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1050-2019%22&limit=1).
Why it’s dangerous
The presence of N-Methylnitrosobutyric acid (NMBA) indicates a deviation from Current Good Manufacturing Practices. Nitrosamines like NMBA are potential genotoxic impurities, which is why their detection in pharmaceutical products triggers a recall to prevent patient exposure.
Who’s affected
Consumers who purchased Losartan Potassium Tablets, USP, 100 mg from Wal-Mart distribution centers in AR, CA, GA, IN, and MD. Patients taking this specific medication are at risk of exposure to the identified impurity.
How to tell if you have this one
Check your medication bottle for the National Drug Code (NDC) 68645-579-54. Look for specific lot numbers including 180886, 180887, 180888, 180905, 181123, 181124, 181125, 181351, 181352, 181551, 181628, 181629, 181727, 181728, 181890, 181891, 181897, 182114, 182119, and 182120. Verify the expiration dates associated with these lots: Nov-19, Dec-19, Sep-2019, Oct-2019, Aug-19, Jun-20, and Mar-20.
- Brand
Legacy Pharmaceutical Packaging- Category
Drug
All 3 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Ongoing- Distribution
Wal-Mart distribution centers in AR, CA, GA, IN and MD
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-1048-2019 | Losartan Potassium Tablets, USP, 25 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045 NDC 68645-577-54; Lots: 180952, exp Oct-19, 180953, exp Dec-19, 181086, exp Sep-19, 181572, exp Jan-20 | 456,732 bottles |
| D-1049-2019 | Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-578-54; Lots: 180921, exp Sep-19, 180922, exp Oct-19, 180923, 180924, 181118, exp Nov-19, 181119, exp Oct-19, 181407, exp Nov-19, 181408, exp Dec-19, 181573, 181725, 181726, exp Feb-20, 181948, exp Mar-20, 181960, exp Feb-20, 182385, 182386, 182387, exp Mar-20 | 2,851,284 bottles |
| D-1050-2019 | Losartan Potassium Tablets, USP, 100 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-579-54; 180886, Nov-19; 180887, 180888, 180905, Dec-19; 181123, Sep-2019; 181124, Oct-2019, 181125, Aug-19, 181351, Nov-19, 181352, Dec-19, 181551, Nov-19, 181628, 181629, 181727, 181728, Jun-20; 181890, Mar-20; 181891, 181897, Jun-20; 182114, Mar-20; 182119, 182120, Jun-20 | 2,497,856 bottles |
What to do — step by step
Stop taking the medication
Do not consume any Losartan Potassium Tablets, USP, 100 mg from the recalled lots due to the presence of impurity NMBA.
Contact your healthcare provider
Speak with your doctor or pharmacist immediately to discuss alternative treatment options and how to safely discontinue this medication.
Where it went and when
Where it was distributed
Distributed in 5 states.
FDA distribution: “Wal-Mart distribution centers in AR, CA, GA, IN and MD” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Arkansas, California, Georgia, Indiana, Maryland.
Recall timeline
FDA published this recall 26 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Questions people ask
Where were these recalled tablets sold?
The affected bottles were distributed by Wal-Mart to distribution centers in Arkansas (AR), California (CA), Georgia (GA), Indiana (IN), and Maryland (MD).
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1050-2019 (March 1, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1050-2019 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.